Bryostatin

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Tuesday, April 9, 2024
Psilocybin, Alzheimer's disease, Partnership, Research, Parkinson's disease, Inflammatory bowel disease, Therapy, Intellectual property, Bryostatin, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Retrieved on: 
Thursday, July 13, 2023
IBRO, Therapy, DSMB, Bryostatin, NIH, MCI, National Institutes of Health, Dementia, Bangladesh Technical Education Board, Data monitoring committee, International Brain Research Organization, Congress, Acquisition, Patient, SIB, AD, World Congress, MMSE, Alzheimer's disease, Safety, Pharmaceutical industry, Neuroscience

NEW YORK, July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that an abstract featuring secondary endpoint data of its National Institutes of Health (NIH) sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience to be held in September 2023 in Spain.

Key Points: 
  • All patients were randomized with respect to treatment groups, with safety checked by an independent Data Safety Monitoring Board (DSMB).
  • Data also showed statistical significance in exploratory secondary endpoints for this Severe Cohort (MMSE 10-14 stratum), and post hoc analysis was positive.
  • "We are pleased that the IBRO World Congress has recognized our findings on the cognitive benefits of Bryostatin-1 for advanced and severe AD patients.
  • As of March 31, 2023, Synaptogenix maintains a clean capital structure and strong cash position of $35.8 million.

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Retrieved on: 
Wednesday, October 19, 2022
U.S. Securities and Exchange Commission, Orphan, Disease, Government, Neurodegeneration, Stroke, Multiple sclerosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Drug development, Alzheimer's disease, Security (finance), Fragile X syndrome, Food, Bryostatin, Neuron, Company, Safety, AD, Brain, Death, Pharmaceutical industry

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that President and Chief Scientific Officer Daniel L. Alkon, M.D. will deliver a presentation and host meetings with investors at the upcoming ThinkEquity Conference.

Key Points: 
  • Now is one of the most exciting times in our Company history as we await topline data from our Phase 2 trial."
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Retrieved on: 
Friday, August 12, 2022
Fragile X syndrome, U.S. Securities and Exchange Commission, TD Ameritrade Network, NIH, Food, Clinical trial, Alzheimer's disease, Bryostatin, Security (finance), Government, Patient, Stroke, Company, Therapy, Neurodegeneration, Safety, Drug development, TD, Orphan, National, AD, National Institutes of Health, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Pharmaceutical industry

"Trading 360"with Nicole Petallidesfeatures Wall Street's best traders, analysts and technicians to break down sectors and stocks moving markets.

Key Points: 
  • "Trading 360"with Nicole Petallidesfeatures Wall Street's best traders, analysts and technicians to break down sectors and stocks moving markets.
  • "Trading 360"with Nicole Petallides focuses on disruptive companies and new technologies driving marketheadlines while providing investors a 360-degree actionable approach to trading.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix to Present at the Cell Symposium

Retrieved on: 
Tuesday, May 17, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Epigenetics, Food, U.S. Securities and Exchange Commission, Cell Press, Patient, Poster, Alzheimer's disease, Government, Stroke, National Institutes of Health, Bryostatin, AD, Fragile X syndrome, Neurodegeneration, Multiple sclerosis, Safety, Apolipoprotein E, Orphan, Drug development, Therapy, National, Allele, Security (finance), Pharmaceutical industry

"We are excited to present at this event sponsored by Cell Press, one of the leading scientific publications in our space.

Key Points: 
  • "We are excited to present at this event sponsored by Cell Press, one of the leading scientific publications in our space.
  • Synaptogenix is currently conducting a six-month, National Institutes of Health ("NIH") supported Phase 2 trial for advanced AD patients who have previously shown actual improvement over baseline with Bryostatin treatment."
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Retrieved on: 
Tuesday, March 29, 2022
Company, Drug development, Multiple sclerosis, Orphan, Therapy, AD, Neurodegeneration, Food, U.S. Securities and Exchange Commission, Fragile X syndrome, Government, Safety, Stroke, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bryostatin, Alzheimer's disease, Security (finance), Pharmaceutical industry

NEW YORK, March 29, 2022 /PRNewswire/ --Synaptogenix, Inc.(Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29th at 2pm ET.

Key Points: 
  • NEW YORK, March 29, 2022 /PRNewswire/ --Synaptogenix, Inc.(Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29th at 2pm ET.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Tuesday, September 28, 2021
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Clinical trial, Neurodegeneration, Fragile X syndrome, Market capitalization, Orphan, Security (finance), Therapy, Stroke, Conference, U.S. Securities and Exchange Commission, Alzheimer's disease, Bryostatin, Company, Drug development, Safety, Government, Multiple sclerosis, Pharmaceutical industry

NEW YORK, Sept. 28, 2021 /PRNewswire/ --Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be participating at the Benzinga Healthcare Small Cap Conference being held September 29-30, 2021.

Key Points: 
  • NEW YORK, Sept. 28, 2021 /PRNewswire/ --Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be participating at the Benzinga Healthcare Small Cap Conference being held September 29-30, 2021.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • The Benzinga Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the healthcare Small Cap audience in an intimate, virtual setting.

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Friday, September 10, 2021

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.The conference is being heldas a virtual conference on September 13-15, 2021.

Key Points: 
  • NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.The conference is being heldas a virtual conference on September 13-15, 2021.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Retrieved on: 
Monday, July 26, 2021
Toll-free telephone number, Conference call, Dial

"Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.

Key Points: 
  • "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.
  • The abstract can be accessed via the following link: https://www.synaptogen.com/wp-content/uploads/2021/07/ESCIOBAADP.pdf
    Also, as previously announced, Synaptogenix will hold a conference call for investors to discuss its abstract.
  • The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054.
  • These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission.

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Retrieved on: 
Wednesday, July 21, 2021
Bryostatin, Macrolides, Total synthesis

The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054.

Key Points: 
  • The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.